Sightera Biosciences closes €3M pre-seed to expand its patient-derived AI drug discovery platform

Tech.eu · 2 months ago · 11

Sightera Biosciences, a Belgian techbio company, raised €3 million in pre-seed funding to expand its generative AI platform for discovering small-molecule drugs trained on patient-derived biological samples. The company uses proprietary datasets from patient organoids and disease models to train AI that designs drug candidates based on actual human disease biology rather than chemical properties alone. The funding will accelerate development of its oncology and fibrosis pipeline and support expansion of partnerships and team growth.